// App-Quantinova.ai

DXT20 : Reduced Rate of Brain Atrophy after 5 Years of Ocrelizumab Treatment in Patients with Ppms from the Phase III Oratorio Trial

Researchers

Presenter

  • Gavin Giovannoni

Principal Investigators

  • Stephen L Hauser

  • Xavier Montalban

  • Jerry S Wolinsky

  • Kalpesh Prajapati

  • Lahar Mehta

  • Hans-Peter Hartung

  • Ludwig Kappo

  • Anthony Traboulsee

  • Karine Coutant

  • Fabian Model

  • Douglas L Arnold

Medical Centers

  • Queen Mary University, London, UK

  • University of California, San Francisco, CA

  • Division of Neurology, University of Toronto Vall d'Hebron University Hospital

  • McGovern Medical School at the University of Texas Health Science Center, Houston, TX

  • Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Dusseldorf

  • University Hospital Basel, University of Basel

  • University of British Columbia,

  • NeuroRx Research,McGill University

Locations

  • United Kingdom

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • GC Vitamin D Binding Protein

Drug/Treatment

  • Ocrelizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01194570

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved